Skip to main content
International Journal of Clinical and Experimental Pathology logoLink to International Journal of Clinical and Experimental Pathology
. 2015 Nov 1;8(11):15039–15041.

Perianal multiple Bowen’s disease: a case report

Wei Zhan 1,*, Xin Liao 2,*, Tian Tian 3, Ru-Yi Zhang 1, Po Li 4, Xiao-Ping Wu 1, Qing-Hua Ji 1, Qin Yang 3
PMCID: PMC4713628  PMID: 26823842

Abstract

Bowen’s disease, also known as an intraepithelial squamous cell neoplasia, is a carcinoma in situ firstly reported in 1912 by a dermatologist named Bowen from the United States [1]. About 3%~5% of Bowen’s disease might develop into invasive squamous cell carcinomas of mocusa and skin [2]. Surgical resection is preferred because of its low recurrence. Here we reported a rare Bowen’s disease case presented with multiple perianal lesions that were given surgical resection, but relapsed after 2 years.

Keywords: Bowen’s disease, perianal, multiple

Introduction

A 54-year-old woman had small perianal mass accompanied with itching for more than 6 years. Knee-chest position rectal examination found genital leukoplakia and four irregular masses at anal 3, 5-7, and 12 point with the size of 0.5 cm × 0.5 cm, 1.0 cm × 1.0 cm and 1.5 cm × 1.3 cm, 0.8 cm × 1.0 cm respectively. The edge of mass was pink, eczema-like changes on its surface, a sense of touch itching associated with pain and no bleeding. Mass at 5-7 point was surgically removed and the pathology revealed anal Bowen’s disease. An anal biopsy for the lesion at 12 point was performed and the pathology was the same result. Then the lesion at anal 3 and 12 points were surgically removed (Figure 1).

Figure 1.

Figure 1

Pathological changes of the surgically removed tissue. A: It was showed as epithelial hyperplasia, loss of polarity of epithelium, and cell atypia while still limited within the epithelial (HE × 40). B: It was showed as dysplastic epithelial cells occupied the whole floor, a large stained mitosis, and cell atypia limited within the epithelium (HE × 400).

Two years after operation, it was found that there are 3 taupe banded lesions at 12 point (Figure 2). The lesion was about 0.1 cm × 1.0 cm. The pathology of biopsy showed the recurrence. The patient was given resection after biopsy.

Figure 2.

Figure 2

Gross appearance of the recurrent lesion.

Discussion

Bowen’s disease was previous described as related with multiple factors including ionizing radiation, sun exposure, arsenic exposure [3], immunosuppression [4], human papilloma virus infection [5] genetic factors, trauma, chemical carcinogens, X-ray radiation. Bowen’s disease can occur in any age, most in the 20-45 years old, male and female incidence rate is almost equal [6]. In female patients, it is also associated with vulvar and cervical intraepithelial neoplasia [7]. As for this patient, she reported a history of squamous cell cancer of the uterus. Perianal Bowen’s disease is characterized by infrequent, mild clinical manifestations, such as burning or itching [8], perianal lump or bleeding in more than a third of patients [9], and shows perianal rash-like appearance.

The diagnosis of Bowen’s disease depends on pathology [10]. A therapeutic regimen has not been recommended [11]. Resection was the preferred treatment. It is required to remove the whole lesion even to the edge of the healthy tissue so as to reduce the recurrence rate [12]. Recently multiple treatment modes are applied including Imiquimod [13], fluorouracil for external use [14], laser therapy, radiotherapy and photodynamic therapy [2]. Among these, Radiotherapy was reported to be suitable for larger lesions and recurrent lesions [11]. Photodynamic therapy is a non-invasive method, while it may cause treatment failure especially in older patients and the lesions with severe atypia [16]. In this patient, the recurrence after surgery was probably related with the residual of operation.

Disclosure of conflict of interest

None.

References

  • 1.Vasani RJ. Bowen’s disease on the dorsum of hand. Indian Dermatol Online J. 2015;6:62–63. doi: 10.4103/2229-5178.148956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Neubert T, Lehmann P. Bowen’s disease-a review of newer treatment options. Ther Clin Risk Manag. 2008;4:1085–1095. [PMC free article] [PubMed] [Google Scholar]
  • 3.Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum Toxicol. 1989;8:99–104. doi: 10.1177/096032718900800203. [DOI] [PubMed] [Google Scholar]
  • 4.Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen’s disease) in immunocompromised patients. J Am Acad Dermatol. 2008;59:68–71. doi: 10.1016/j.jaad.2008.03.028. [DOI] [PubMed] [Google Scholar]
  • 5.Derancourt C, Mougin C, Chopard Lallier M, Coumes-Marquet S, Drobacheff C, Laurent R. Oncogenic human papillomaviruses in extragenital Bowen disease revealed by in situ hybridization. Ann Dermatol Venereol. 2001;128:715–718. [PubMed] [Google Scholar]
  • 6.Bertagni A, Vagliasindi A, Ascari Raccagni A, Valmori L, Verdecchia GM. Perianal Bowen’s disease: a case report and review of the literature. Tumori. 2003;89:16–18. [PubMed] [Google Scholar]
  • 7.Salati SA, Al Kadi A. Anal cancer-a review. Int J Health Sci (Qassim) 2012;6:206–230. doi: 10.12816/0006000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Leonard D, Beddy D, Dozois EJ. Neoplasms of anal canal and perianal skin. Clin Colon Rectal Surg. 2011;24:54–63. doi: 10.1055/s-0031-1272824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Margenthaler JA, Dietz DW, Mutch MG, Birnbaum EH, Kodner IJ, Fleshman JW. Outcomes, risk of other malignancies, and need for formal mapping procedures in patients with perianal Bowen’s disease. Dis Colon Rectum. 2004;47:1655–1660. doi: 10.1007/s10350-004-0662-4. [DOI] [PubMed] [Google Scholar]
  • 10.Gandhi AK, Laviraj MA, Kashyap L, Purkait S, Sharma DN, Julka PK, Rath GK. Recurrent Bowen’s disease of scalp treated with high dose rate surface mold brachytherapy: a case report and review of the literature. J Contemp Brachytherapy. 2015;6:389–394. doi: 10.5114/jcb.2014.47704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’s disease) 2014. Br J Dermatol. 2014;170:245–260. doi: 10.1111/bjd.12766. [DOI] [PubMed] [Google Scholar]
  • 12.Westers-Attema A, van den Heijkant F, Lohman BG, Nelemans PJ, Winnepenninckx V, Kelleners-Smeets NW, Mosterd K. Bowen’s Disease: A Six-year retrospective study of treatment with emphasis on resection margins. Acta Derm Venereol. 2014;94:431–435. doi: 10.2340/00015555-1771. [DOI] [PubMed] [Google Scholar]
  • 13.Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, Motley RJ. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermato. 2006;54:1025–1032. doi: 10.1016/j.jaad.2006.01.055. [DOI] [PubMed] [Google Scholar]
  • 14.Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, Ibbotson S, Khemis A, Wolf P. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol. 2006;142:729–735. doi: 10.1001/archderm.142.6.729. [DOI] [PubMed] [Google Scholar]
  • 15.Anna Z, John K, Maria T, George K, Ivelina B, Ioanna K, Georgia S, Vassilis K. The potential role of radiation therapy in Bowen’s disease: a review of the current literature. Rev Recent Clin Trials. 2012;7:42–46. doi: 10.2174/157488712799363271. [DOI] [PubMed] [Google Scholar]
  • 16.Westers-Attema A, Lohman BG, van den Heijkant F, Nelemans PJ, Winnepenninckx VJ, Kelleners-Smeets NW, Mosterd K. Photodynamic therapy in Bowen’s disease: influence of histological features and clinical characteristics on its success. Dermatology. 2015;230:55–61. doi: 10.1159/000366500. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Clinical and Experimental Pathology are provided here courtesy of e-Century Publishing Corporation

RESOURCES